Skip to content

MSCs Therapy for Cerebral Palsy

Bone Marrow Stem Cells Transplantation for the Treatment of Cerebral Palsy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04653077
Enrollment
50
Registered
2020-12-04
Start date
2020-12-02
Completion date
2022-12-01
Last updated
2020-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stem Cell Transplant Complications

Brief summary

Cerebral palsy (CP) is the most common physical disability in childhood. CP comprises a heterogeneous group of disorders that are the result of a non-progressive disruption or injury that occurred during fetal brain development or within the first two years of life.

Detailed description

This disruption can result in spasticity, dystonia, muscle contractures, weakness and difficulty in coordination that ultimately affects the ability to control movements. Resultant activity limitations may affect gross motor movements, fine motor movements, speech and communication, as well as eating and drinking.

Interventions

OTHERstem cells

Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.

Sponsors

AMR KHALIL ORTHOPEDIC SURGERY CENTER
CollaboratorUNKNOWN
Aljazeera Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
2 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* • Must be more than 2 year of age and less than 12 years of age at the time of screening for inclusion in the study. * Clinical evidence of a non-progressive motor disability due to brain dysfunction.

Exclusion criteria

* • Intractable seizures * Traumatic brain injury * Genetic disorder * Current Infection * Renal insufficiency * Hepatic disease * HIV+ (as demonstrated by positive blood test) * Immunosuppression

Design outcomes

Primary

MeasureTime frameDescription
Changes in Motor Performance.6 monthsthe number of patients who will have changes in motor performance

Countries

Egypt

Contacts

Primary Contactamr khalil
amrkhalil273@gmail.com01223292124

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026